$VNDA News

Vanda Pharmaceuticals Receives Japanese Orphan Drug Designation For Imsidolimab In Generalized Pustular Psoriasis

Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss

HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21

Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript

VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Misses Q1 2026 Estimates as Top-Line Growth Slows

Vanda Pharmaceuticals' NEREUS Now Commercially Available Throughout U.S. To Prevent Vomiting Induced By Motion In Adults

Vanda Pharma Highlights Legislative Proposal Contained In FDA's FY 2027 Congressional Budget Justification; Proposal Will Eliminate Simple Statutory Requirement That FDA Must Review NDA Within 180 Days Of Filing

Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of NEREUS For The Prevention Of Vomiting Induced By GLP-1 Receptor Agonists; Topline Results From Thetis Study Expected By Q4 2026; Phase 2 Study Succeeded And Met Its Primary Endpoint

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

Vanda Pharmaceuticals Advocates For Stronger FDA Measures To Accelerate Shift From Animal Testing To Human-Relevant Methods

Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag

Truist Securities Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces Price Target of $18

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

FDA Grants Vanda Pharma's Request For Formal Evidentiary Public Hearing To Review CDER Proposal To Refuse Approval Of sNDA For HETLIOZ In Treatment Of Jet Lag Disorder

European Medicines Agency Announced Recommended Refusal Of Marketing Authorization For Iloperidone Vanda Pharmaceuticals For Schizophrenia And Manic Or Mixed Episodes Associated With Bipolar I Disorder

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug

Vanda Pharmaceuticals Announces FDA Accepts Its Biologics License Application For Generalized Pustular Psoriasis Treatment